NVIDIA
NVDA
Tesla
TSLA
Taiwan Semiconductor
TSM
Advanced Micro Devices
AMD
Qualcomm
QCOM
US Stock MarketDetailed Quotes
ONVO Organovo Holdings
- 0.435
- -0.008-1.72%
Trading Jan 3 12:24 ET
6.68MMarket Cap-0.42P/E (TTM)
0.470High0.412Low227.55KVolume0.470Open0.443Pre Close100.20KTurnover1.67%Turnover RatioLossP/E (Static)15.37MShares1.74052wk High1.82P/B5.91MFloat Cap0.31552wk Low--Dividend TTM13.59MShs Float273.000Historical High--Div YieldTTM13.17%Amplitude0.315Historical Low0.440Avg Price1Lot Size
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Organovo Holdings Stock Forum
📊⚡️📊
$Applied Therapeutics (APLT.US)$ Crashed after FDA CRL but will resubmit. Dropped from 10 to 1.3 rebounded to 1.95. SI 16%
$PainReform (PRFX.US)$ Microfloat. Up after hours. SI 20%. 0 shares LTB. CTB 436%. If there is no catalyst, microfloats will be a quick play.✔️
$Blue Ocean Acquisition Corp(Delisted) (BOCN.US)$ Merger ...
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
Organovo Holdings (NASDAQ:ONVO)presented Phase 2 clinical trial results for FXR314 at The Liver Meeting. The study involved 214 MASH patients randomized to receive 3mg, 6mg FXR314, or placebo. The drug demonstrated statistically significant liver fat reduction from baseline: 22.8% (3mg) and 17.5% (6mg) versus 6.1% placebo. Notably, >30% MRI-PDFF reduction was ac...
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
Organovo Holdings (Nasdaq: ONVO) announces that its lead clinical stage drug, FXR314, will be featured in an oral presentation at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The presentation, scheduled for November 17, 2024, will be del...
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
Organovo Holdings (Nasdaq: ONVO) presented its outlook and plans at the Jones Trading Healthcare Conference, focusing on FXR314, its treatment for inflammatory bowel disease (IBD). Executive Chairman Keith Murphy highlighted the strong preclinical and human rationale for FXR314 in Phase 2a ulcerative colitis...
NEWS
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
In a significant step forward for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Organovo Holdings Inc. has announced positive Phase 2 trial results for its experimental drug, FXR314. This development marks a pivotal moment in the fight against MASH, a severe form of fatty liver disease that poses a su...
$Organovo Holdings (ONVO.US)$ huge opportunity 💯💯🔥💯🏆🏆🆙🆙💴🆙🏆🏆💯💯🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥
$Organovo Holdings (ONVO.US)$ buy💯💯🔥💯🏆🏆💴🆙🆙🆙🆙
No comment yet